P16 Immunoreactivity Is an Independent Predictor of Tumor Progression in Minimally Invasive Urothelial Bladder Carcinoma
Author:
Publisher
Elsevier BV
Subject
Urology
Reference29 articles.
1. P16 (MTS-1/CDKN2/INK4a) in cancer progression;Rocco;Exp Cell Res,2001
2. P16 (CDKN2) is a major deletion target at 9p21 in bladder cancer;Williamson;Hum Mol Genet,1995
3. Genetic alterations and biological pathways in human bladder cancer;Reznikoff;Urol Oncol,2000
4. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb;Hitchings;Br J Cancer,2004
5. P53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer;Shariat;J Clin Oncol,2004
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Investigation of the Prognostic Significance of Immunohistochemical Expression of p16 and p27 in Bladder Tumors;2024-02-07
2. Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors;Acta Oncologica;2023-11-08
3. p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India;Journal of Cancer Research and Therapeutics;2023
4. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer;Scientific Reports;2022-10-05
5. Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation;International Journal of Molecular Sciences;2022-07-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3